Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program

E. Verzoni; G. Cartenì; E. Cortesi; D. Giannarelli; A. De Giglio; R. Sabbatini; S. Buti; S. Rossetti; F. Cognetti; F. Rastelli; A. Sobrero; D. Turci; C.N. Sternberg; C. Porta; F. Cappuzzo; G. Tortora; D. Tassinari; S. Panni; A. Pazzola; G. Surico; A. Raimondi; U. De Giorgi; G. Procopio

doi:10.1186/s40425-019-0579-z

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program

E. Verzoni, G. Cartenì, E. Cortesi, D. Giannarelli, A. De Giglio, R. Sabbatini, S. Buti, S. Rossetti, F. Cognetti, F. Rastelli, A. Sobrero, D. Turci, C.N. Sternberg, C. Porta, F. Cappuzzo, G. Tortora, D. Tassinari, S. Panni, A. Pazzola, G. SuricoA. Raimondi, U. De Giorgi, G. Procopio

Research output: Contribution to journal › Article

Original language	English
Journal	Journal for ImmunoTherapy of Cancer
Volume	7
Issue number	1
DOIs	https://doi.org/10.1186/s40425-019-0579-z
Publication status	Published - 2019

Cite this

Verzoni, E., Cartenì, G., Cortesi, E., Giannarelli, D., De Giglio, A., Sabbatini, R., Buti, S., Rossetti, S., Cognetti, F., Rastelli, F., Sobrero, A., Turci, D., Sternberg, C. N., Porta, C., Cappuzzo, F., Tortora, G., Tassinari, D., Panni, S., Pazzola, A., ... Procopio, G. (2019). Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program. Journal for ImmunoTherapy of Cancer, 7(1). https://doi.org/10.1186/s40425-019-0579-z

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program. / Verzoni, E.; Cartenì, G.; Cortesi, E.; Giannarelli, D.; De Giglio, A.; Sabbatini, R.; Buti, S.; Rossetti, S.; Cognetti, F.; Rastelli, F.; Sobrero, A.; Turci, D.; Sternberg, C.N.; Porta, C.; Cappuzzo, F.; Tortora, G.; Tassinari, D.; Panni, S.; Pazzola, A.; Surico, G.; Raimondi, A.; De Giorgi, U.; Procopio, G.

In: Journal for ImmunoTherapy of Cancer, Vol. 7, No. 1, 2019.

Research output: Contribution to journal › Article

Verzoni, E, Cartenì, G, Cortesi, E, Giannarelli, D, De Giglio, A, Sabbatini, R, Buti, S, Rossetti, S , Cognetti, F, Rastelli, F, Sobrero, A, Turci, D, Sternberg, CN, Porta, C, Cappuzzo, F, Tortora, G, Tassinari, D, Panni, S, Pazzola, A, Surico, G, Raimondi, A , De Giorgi, U & Procopio, G 2019, 'Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program', Journal for ImmunoTherapy of Cancer, vol. 7, no. 1. https://doi.org/10.1186/s40425-019-0579-z

Verzoni E, Cartenì G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R et al. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program. Journal for ImmunoTherapy of Cancer. 2019;7(1). https://doi.org/10.1186/s40425-019-0579-z

Verzoni, E. ; Cartenì, G. ; Cortesi, E. ; Giannarelli, D. ; De Giglio, A. ; Sabbatini, R. ; Buti, S. ; Rossetti, S. ; Cognetti, F. ; Rastelli, F. ; Sobrero, A. ; Turci, D. ; Sternberg, C.N. ; Porta, C. ; Cappuzzo, F. ; Tortora, G. ; Tassinari, D. ; Panni, S. ; Pazzola, A. ; Surico, G. ; Raimondi, A. ; De Giorgi, U. ; Procopio, G. / Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program. In: Journal for ImmunoTherapy of Cancer. 2019 ; Vol. 7, No. 1.

@article{5f172bcaf09b453fa94280e306449c8d,

title = "Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program",

author = "E. Verzoni and G. Carten{\`i} and E. Cortesi and D. Giannarelli and {De Giglio}, A. and R. Sabbatini and S. Buti and S. Rossetti and F. Cognetti and F. Rastelli and A. Sobrero and D. Turci and C.N. Sternberg and C. Porta and F. Cappuzzo and G. Tortora and D. Tassinari and S. Panni and A. Pazzola and G. Surico and A. Raimondi and {De Giorgi}, U. and G. Procopio",

note = "Cited By :10 Export Date: 13 February 2020",

year = "2019",

doi = "10.1186/s40425-019-0579-z",

language = "English",

volume = "7",

journal = "Journal for ImmunoTherapy of Cancer",

issn = "2051-1426",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program

AU - Verzoni, E.

AU - Cartenì, G.

AU - Cortesi, E.

AU - Giannarelli, D.

AU - De Giglio, A.

AU - Sabbatini, R.

AU - Buti, S.

AU - Rossetti, S.

AU - Cognetti, F.

AU - Rastelli, F.

AU - Sobrero, A.

AU - Turci, D.

AU - Sternberg, C.N.

AU - Porta, C.

AU - Cappuzzo, F.

AU - Tortora, G.

AU - Tassinari, D.

AU - Panni, S.

AU - Pazzola, A.

AU - Surico, G.

AU - Raimondi, A.

AU - De Giorgi, U.

AU - Procopio, G.

N1 - Cited By :10 Export Date: 13 February 2020

PY - 2019

Y1 - 2019

U2 - 10.1186/s40425-019-0579-z

DO - 10.1186/s40425-019-0579-z

M3 - Article

VL - 7

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

ER -

Access to Document

10.1186/s40425-019-0579-z

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063937275&doi=10.1186%2fs40425-019-0579-z&partnerID=40&md5=c1bd574fcf7711334a5bc654878a9d04

Projects

MAUGERI - MEDICINA CLINICA-SPECIALISTICA

Project: Other project

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program

Cite this

Access to Document

Related content

Projects

MAUGERI - MEDICINA CLINICA-SPECIALISTICA